SCHEMBL5495932

SCHEMBL5495932

COc1ccc(NC(=O)Nc2ncc(-c3ccsc3)cn2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.54
SMN1; SMN2 Q16637 7/20 0.54
NPC1 O15118 6/20 0.54
TP53 P04637 5/20 0.52
TSHR P16473 2/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 4/20 0.49
KDM4E B2RXH2 4/20 0.49
MEN1 O00255 5/20 0.47
MAPT P10636 5/20 0.47
KMT2A Q03164 5/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
SAE1 Q9UBE0 1/20 0.47
UBA2 Q9UBT2 1/20 0.47
PDGFRB P09619 2/20 0.46
PDGFRA P16234 2/20 0.46
GAA P10253 1/20 0.46
ESR2 Q92731 1/20 0.46
NOX1 Q9Y5S8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5495504 0.84 CNR1 (0.47) RAB9ASMN1; SMN2NPC1TP53LMNA
SCHEMBL5495854 0.82 PDGFRB (0.52) RAB9ASMN1; SMN2NPC1LMNAKDM4E
SCHEMBL5504631 0.77 AURKA (0.49) RAB9ASMN1; SMN2NPC1LMNAMEN1
SCHEMBL5501205 0.74 CTSC (0.62) RAB9ASMN1; SMN2NPC1POLBMEN1
SCHEMBL11092496 0.73 RAB9A (1.00) RAB9ASMN1; SMN2NPC1TP53TSHR
SCHEMBL5513136 0.72 EGFR (0.47) RAB9ASMN1; SMN2NPC1TP53TSHR
SCHEMBL14342357 0.71 CTSC (0.46)
SCHEMBL5496471 0.70 CTSC (0.49) RAB9ASMN1; SMN2NPC1KDM4EMEN1
SCHEMBL20764040 0.69 SMN1; SMN2 (0.76) RAB9ASMN1; SMN2NPC1TP53LMNA
SCHEMBL17628550 0.69 RAB9A (0.88) RAB9ASMN1; SMN2NPC1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US claimed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP claimed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO claimed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP disclosed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293484-A1 Thiophene Heteroaryl Amines TTK, CHEK2, ABL1 RAB9A 937/4885SMN1; SMN2 3601/4885NPC1 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.